Pipeline

In order to demonstrate the diversity of the AMR-dedicated SMEs’ pipeline in Europe, the BEAM Alliance has collated its members’ technological assets into a comprehensive portfolio. While its size is already impressive, the proposed categorization approach is further revealing the high level of innovativeness that is being deployed, both at clinical and preclinical stages.

BEAM Infection Curve (BIC)

BEAM Infection Curve (BIC)

Pipeline Rx

Click on column headers to sort the table

memberproductbic*typetargets/indicationsdevelopment
stage
NanoRevivStaph-EX3aOtherBone & Joint InfectionsPre-clinical
PHAXIAMPHAXIAM NA3aPhage Diabetic foot ulcer with anti S.aureus phage therapy Pre-clinical
PHAXIAMPHAXIAM NA3aPhageHospital acquired or ventilator- acquired bacterial pneumoniae with anti-P.aeruginosa Phage therapy Pre-clinical
PHAXIAMPP970, PP1002, PP1151, PP20003aPhageComplicated Urinary Tract Infection (cUTI) with anti-E. coli phage therapyIND/CTA ready
PHAXIAMPP1493/PP18153aPhageEndocarditis with anti-S.aureus phage therapy Phase I
PHAXIAMPP1493/PP18153aPhageProsthetic Joint Infection (PJI) with anti-S.aureus phage therapy Phase II
discoveric bio betaNIDB-3002AntibodyNon-cystic fibrosis bronchiectasisLead opt
discoveric bio betaNIDB-3001AntibodyBloodstream infectionsLead opt
Omnix MedicalOMN703a/5aProtein/PeptideP. aeruginosa; Escherichia coli; K. pneumoniae; E. faceum / Acne or Atopic-DermatitisLead opt
Omnix MedicalOMN513a/5aProtein/PeptideP. aeruginosa; Escherichia coli; K. pneumoniae; E. faceum; S. aureus; B. oleronius / Cystic Fibrosis (CF)Lead opt
VibioSphenTherapeptics3aProtein/PeptideA. baumannii; P. aeruginosa; Klebsiella pneumoniae; Staphylococcus aureus; Clostridioides difficile/Intra-abdominal infections (cIAI)Lead opt
Phico Therapeutics LtdSASPject™ PT93aPhageS. aureus/Animal HealthLead opt
Phico Therapeutics LtdSASPject™ PT83aPhageS. aureus/BacteraemiaLead opt
Phico Therapeutics LtdSASPject™ PT3.93aPhageP. aeruginosa/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Pre-clinical
BasileaNovel target (IspF inhibitor)3aNMEA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp.; Proteus spp.; Salmonella spp; Shigella spp.; Other Enterobacterales / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Discovery
BasileaNovel target (DXR inhibitor)3aNMEA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp.; Proteus spp.; Salmonella spp; Shigella spp.; Other Enterobacterales / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Lead opt
BasileaNovel class3aNMEA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp.; Proteus spp.; Salmonella spp; Shigella spp.; Other Enterobacterales / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Lead opt
BasileaNovel class3aNMEAspergillus spp; Mucorales; Fusarium spp; Scedosporium spp; Cryptococcus spp; Candida spp / Invasive fungal diseaseLead opt
Destiny Pharma plcXF-731bNMEStaphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / Prevention of oral mucositisPre-clinical
Destiny Pharma plcXF-733aNMEStaphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / BurnsPre-clinical
Destiny Pharma plcXF-733aNMEStaphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / Treatment of chronic rhinosinusitisPre-clinical
Destiny Pharma plcXF-733aNMEStaphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / Cystic fibrosis associated infectionsPre-clinical
Destiny Pharma plcXF-733aNMEStaphylococcus aureus; Enterococcus faecium; Streptococcus pneumoniae / Prevention of post-surgical infectionPhase II
Destiny Pharma plcNTCD-M31bNMEToxigenic strains of C. difficile / Prevention of recurrence of C diff infectionPhase II
Destiny Pharma plcSPOR-COV1aNMERespiratory viruses, SARS-COV-2 & Influenza / Prevention of viral respiratory infectionsPre-clinical
Infex Therapeutics LtdRESP-X3cAntibodyP. aeruginosa / Non-cystic-fibrosis bronchiectasisPhase I
Infex Therapeutics LtdMET-X3dNMEA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp. / Complicated urinary tract infections (cUTI), HAP, VAP, bloodstream infections, intra-abdominal infectionsPre-clinical
Infex Therapeutics LtdCOV-X-OtherPan-coronavirus / Coronavirus infectionsLead opt
Infex Therapeutics LtdRDX-023aNMEA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp. / Gram-negative AMR infectionsDiscovery
Infex Therapeutics LtdPAN-X-OtherPan-coronavirus / Coronavirus infectionsDiscovery
AdjuTec Pharma ASAPC2473dNMEEscherichia coli; Klebsiella pneumoniae / complicated urinary tract infections (cUTI)Pre-clinical
Ultupharma ABULT23aNMEA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Salmonella spp; Shigella spp.; Helicobacter pylori; Haemophilus influenzae; Staphylococcus aureus; Streptococcus pneumoniae / Bloodstream infectionsPre-clinical
Ultupharma ABULT33aProtein/PeptideA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Staphylococcus aureus / Bloodstream infectionsLead opt
VAXDYNKapaVax1aVaccineKlebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii/Community acquired pneumonia (CAP) and other upper respiratory infections (URTI) (sinusitis/otitis media etc)Pre-clinical
F2G LtdOlorofim3aNMEDHODH inhibitor/Aspergillosis refractory, resistant or intolerant; Lomentospora prolificans, Scedosporium, Fusarium and Scopulariopsis species; Coccidioidomycosis refractoryPhase III
AdjuTec Pharma ASAPC1483dNMEKlebsiella pneumoniae; Enterobacter spp / complicated urinary tract infections (cUTI)IND/CTA ready
Debiopharm InternationalDebio 1454/S3aNMEA. baumannii/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Lead opt
OLGRAMOl20-015aProtein/PeptideP. aeruginosa; Broad-spectrum G+/G-/Cystic fibrosis associated infectionsPre-clinical
Selmod GmbHslm 5003aNMEEscherichia coli; Broad-spectrum G+/G-/Complicated urinary tract infections (cUTI)Pre-clinical
Selmod GmbHslm 4003aNMEA. baumannii; Broad-spectrum G+/G-/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Pre-clinical
Selmod GmbHslm 3003aNMEKlebsiella pneumoniae; Broad-spectrum G+/G-/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Pre-clinical
Selmod GmbHslm 2003aProtein/PeptideCandida albicans, Aspergillus fumigatus, Candida auris/Invasive aspergillosis, Oral Candidiasis, Bronchopulmonary aspergillosisLead opt
Selmod GmbHslm 1003aNMECandida albicans, Aspergillus fumigatus, Candida auris/Invasive aspergillosis, Oral Candidiasis, Bronchopulmonary aspergillosisLead opt
BioNTech R&DPM-4773aProtein/PeptideGardnerella/Bacterial vaginosisPre-clinical
AiCuris Anti-infective Cures AGNPI Scaffolds3aNMEUndisclosed/Healthcare-asscoiated infectionsLead opt
AiCuris Anti-infective Cures AGMacrocyles3aNMEUndisclosedLead opt
Assuré Medical LimitedSol-UTI1bOtherP. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Proteus spp.; Staphylococcus aureus / Uncomplicated urinary tract infections (uUTI)Pre-clinical
BioVersys AGBV1003aNMEA. baumannii/HAP, VAP, BSIPhase I
ABAC therapeuticsABAC-402443aNMEStaphylococcus aureus/Hospital infectionsLead opt
ABAC therapeuticsABAC-404113aNMEStreptococcus pneumoniae/Community acquired pneumonia (CAP) and other upper respiratory infections (URTI) (sinusitis/otitis media etc)Lead opt
ANTABIO S.A.SSBLi (ANT3310)3dNMEA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp.; Proteus spp.; Salmonella spp; Shigella spp.; Other Enterobacterales; Haemophilus influenzae / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP) IND/CTA ready
VibioSphenSativa3bNMEP. aeruginosaPre-clinical
VAXDYNAcinetoVax1aVaccineAcinetobacter baumannii/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Pre-clinical
QureTech Bio ABTIB3aNMEC. trachomatis / Ocular Chlamydia infectionLead opt
QureTech Bio ABGmP3dNMEStaphylococcus aureus; Enterococcus faecium; Clostridioides difficile; E. faecalis; S. epidermidis / Complicated urinary tract infections (cUTI)Lead opt
QureTech Bio ABCIB3aNMEC. trachomatis / Genital Chlamydia infectionLead opt
QureTech Bio ABMTI3dNMEMycobacterium tuberculosis / TuberculosisLead opt
Omnix MedicalOMN63a/5aProtein/PeptideA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Phase I
Northern Antibiotics Oy (Ltd)NAB8153aProtein/PeptideA. baumannii; Enterobacter spp./Complicated urinary tract infections (cUTI)Lead opt
Northern Antibiotics Oy (Ltd)NAB7393aProtein/PeptideA. baumannii; Enterobacter spp./Complicated urinary tract infections (cUTI)Lead opt
Mutabilis SAS2G-Dabocin3aNMEEnterobacterales, P. aeruginosa, A. baumannii/Complicated urinary tract infections (cUTI)Lead opt
Mutabilis SASEBL-14633aNMEEnterobacterales/Complicated urinary tract infections (cUTI)Pre-clinical
IMMUNETHEP, SAUnimab3cAntibodyEscherichia coli; Klebsiella pneumoniae; Staphylococcus aureus; Streptococcus pneumoniae; S. agalactiae/Bloodstream infectionsPre-clinical
IMMUNETHEP, SAPNV1aVaccineS. aureus, E. Coli, ETEC/Bloodstream infections, Community acquired pneumonia (CAP) and other upper respiratory infections (URTI) (sinusitis/otitis media etc)Pre-clinical
Hypharm GmbHHY-1331bPhageStaphylococcus aureus/Nasal colonization with MRSAIND/CTA ready
Eligo BioscienceEB0041bPhageEscherichia coli; Klebsiella pneumoniae/Bloodstream infectionsPre-clinical
Debiopharm InternationalDebio 14533aNMENeisseria gonorrhoeae/GonorrhoeaPre-clinical
Debiopharm InternationalAfabicin3aNMEStaphylococcus spp./ABSSSI (caused by S. aureus), bone and joint infectionsPhase II
Combioxin SACAL024aOtherVirulence factors, broad spectrum Gram+ and Gram-, resistance agnostic/Severe community-acquired bacterial pneumoniaPhase II
Centauri Therapeutics LtdABX013cOtherA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp./Healthcare-asscoiated infectionsPre-clinical
Centauri Therapeutics LtdABX023cOtherP. aeruginosa/Healthcare-asscoiated infectionsPre-clinical
BioVersys AGBV2004aNMEStaphylococcus aureus/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Lead opt
BioVersys AGBV3003aNMEA. baumannii; P. aeruginosa; Enterobacter spp.; Staphylococcus aureus; Enterococcus faecium/Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Lead opt
BioVersys AGBVL-GSK0983dNMEM. tuberculosis/TuberculosisPhase I
BasileaCeftobiprole3aNMES. aureus (including MRSA); Streptococcus spp; Enterococcus faecalis; Enterobacterales; P. aeruginosa / Staphylococcus aureus bacteremia; Acute bacterial skin and skin structure infectionsPhase III
BasileaCeftobiprole3aNMES. aureus (including MRSA); Streptococcus spp; Enterococcus faecalis; Enterobacterales; P. aeruginosa; Haemophilus influenzae / CAP, HAPMarketed
ANTABIO S.A.SPEi (ANT3273)3c/1b/4a/4bNMEP. aeruginosa / Non-CF bronchiectasis associated infectionsPre-clinical
ANTABIO S.A.SMBLi (ANT2681)3dNMEEscherichia coli; Klebsiella pneumoniae; Enterobacter spp.; Citrobacter spp.; Proteus spp.; Salmonella spp; Shigella spp.; Other Enterobacterales; Haemophilus influenzae / Complicated urinary tract infections (cUTI)IND/CTA ready
ALLECRA THERAPEUTICSCefepime / Enmetazobactam3dNMEcUTI, APPhase III
AktheliaAKT-0113cNMEEscherichia coli; Salmonella spp; Broad-spectrum G+/G-/GI infectionsLead opt
AiCuris Anti-infective Cures AGArtilysins3aProtein/PeptideUndisclosed/Bloodstream infections, Diabetic foot infectionLead opt
ABAC therapeuticsABAC-398773aNMEA. baumannii/Hospital infectionsPre-clinical
PreviousPage 1/9show allNext

*BIC: BEAM Infection Curve

The displayed information are not necessarily reflecting the official current position of each BEAM members; please refer to each company’s website for updated information, or contact them directly.

Pipeline Dx

Click on column headers to sort the table

memberkit/testtargeted resultpathogens/indicationslab workflowdevelopment stage
OLM DiagnosticsDermatophyte LFAPathogen IDgenera Trichophyton, Microsporum, Epidermophyton /
Suspected dermatophyte infection of hair, skin or nails
Other sample type
LFIA
<30 minutes
Prototype in Lab
OLM DiagnosticsOcular fungal infectionPathogen IDFusarium, Aspergillus and Candida /
Suspected Fungal keratitis. Risks for developing fungal keratitis include Recent eye trauma, particularly involving plants (for example, thorns or sticks), Underlying eye disease, Weakened immune system and Contact lens use
Other sample type
LFIA
<30 minutes
Prototype in Lab
OLM DiagnosticsOcular fungal infectionPathogen IDFusarium, Aspergillus and Candida /
Suspected Fungal keratitis. Risks for developing fungal keratitis include Recent eye trauma, particularly involving plants (for example, thorns or sticks), Underlying eye disease, Weakened immune system and Contact lens use
Other sample type
PCR/qPCR
<2h
Feasibility Phase
OLM DiagnosticsCocciIDPathogen IDCoccidioides immitis and C. posadasii /
Suspected lung infection in patient who has recently travelled to an endemic area.
From serum/plasma
PCR/qPCR
<2h
Feasibility Phase
OLM DiagnosticsHistoIDPathogen IDHistoplasma capsulatum /
Individuals with cellular immunity deficiencies, such as patients with HIV/AIDS infection. Mild respiratory illness in patients who have recently travelled to highly endemic regions
From serum/plasma
PCR/qPCR
<2h
Development Phase
OLM DiagnosticsMucorIDPathogen IDMucorales species; to include Rhizopus spp., Mucor spp., Lichtheimia spp., Cunninghamella spp., and Rhizomucor spp. /
Suspected fungal infection in patients predisposed by diabetes mellitus, corticosteroids and immunosuppressive drugs, primary or secondary immunodeficiency, hematological malignancies and hematological stem cell transplantation, solid organ malignancies and solid organ transplantation
From serum/plasma
PCR/qPCR
<2h
Development Phase
NG BiotechNG-Test CARBA-R ACINETOAMR Mechanism of Resistance IDA. baumannii, carbapenem-resistant; Enterobacterales, carbapenem-resistant; P. aeruginosa, carbapenem-resistant /
Detection and differentiation of OXA-23, OXA-40/143, OXA-58, NDM, and VIM
From isolated colony
LFIA
<30 minutes
Prototype in Lab
Microbira LtdMAAP-IRPathogen ID75% of Routine Clinical Isolates
Bacteria 94% correct identification: yeasts 95%
From isolated colony
Infrared spectroscopy
<30 minutes
CE-IVD and/or FDA 510k
Microbira LtdMicrobira PrototypeFrom PBS + Isolated colony
Infrared spectroscopy
<4h
Prototype in Lab
Microbira LtdMicrobira PrototypeFrom positive blood culture
Infrared spectroscopy
<30 minutes
Prototype in Lab
NosticsDUTIPathogen IDMultiplex bacteria
Urinary Tract infections
From urine
Surface Enhanced Raman Spectroscopy
<30 minutes
Feasibility Phase
MolsidfMicRapid antimicrobial susceptibility testAll
AST
From isolated colony
Proprietary reader
<4h
Feasibility Phase
MolsidPythia UTIAMR Mechanism of Resistance IDAll
From urine
Microplate-reader
<2h
Development Phase
MolsidPythia StaphAMR Mechanism of Resistance IDS. aureus
From isolated colony
Microplate-reader
<2h
Development Phase
NG BiotechNG-Test Blood Culture PrepAMR Mechanism of Resistance IDAny type of Bacteria /
Isolation of bacteria from blood cultures for downstream processing (LFIA, other)
From positive blood culture
LFIA
<30 minutes
CE-IVD and/or FDA 510k
NG BiotechNG-Test MCR-1AMR Mechanism of Resistance IDEnterobacterales, colistin-resistant /
Detection of colistine resistance
From isolated colony
LFIA
<30 minutes
CE-IVD and/or FDA 510k
NG BiotechNG-Test CTX-M MULTIAMR Mechanism of Resistance IDEnterobacterales, 3rd generation cephalosporin-resistant /
Detection of the 5 most prevalent ESBL CTX-M Groups (1, 2, 8, 9 and 25)
From isolated colony
LFIA
<30 minutes
CE-IVD and/or FDA 510k
NG BiotechNG-Test CARBA 5AMR Mechanism of Resistance IDEnterobacterales, carbapenem-resistant; P. aeruginosa, carbapenem-resistant /
Detection and differentiation of KPC, OXA-48, VIM, IMP and NDM
From isolated colony
LFIA
<30 minutes
CE-IVD and/or FDA 510k
PreviousPage 1/2show allNext

The displayed information are not necessarily reflecting the official current position of each BEAM members; please refer to each company’s website for updated information, or contact them directly.